

**Generic Name:** N/A

**Applicable Drugs (if therapeutic class):**  
Mounjaro™ (tirzepatide)

**Preferred:** N/A

**Non-preferred:** N/A

**Date of Origin:** 8/29/2022

**Date Last Reviewed / Revised:** N/A

## PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through VI are met.)

- I. Diagnosis of type 2 diabetes mellitus.
- II. Documented treatment failure or contraindication to metformin or metformin combination.
- III. Documented treatment failure or contraindication to at least 2 preferred GLP-1 agonists.
- IV. Minimum age requirement: 18 years.
- V. Prescribed in consultation with a specialist (endocrinologist).
- VI. Refer to plan document for the list of preferred products. If requested agent is not listed as a preferred product, must have a documented failure, intolerance, or contraindication to preferred product(s).

## EXCLUSION CRITERIA

- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

## OTHER CRITERIA

- N/A

## QUANTITY / DAYS SUPPLY RESTRICTIONS

- 4 pen injectors per 28 days.

## APPROVAL LENGTH

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing improvement or maintenance with medication.

## REFERENCES

1. Mounjaro [package insert]. Lilly USA; Indianapolis, IN 46285; 2022. Accessed 8/1/22.

2. Riddle, Matthew et al. "American Diabetic Association (ADA): Standards of medical care in diabetes." *Diabetes Care* Vol. 45, Suppl. 1(2022): S1-S264. doi.org/10.2337/dc22-Srev.
3. Rosenstock, Julio, et al. "Efficacy and safety of a novel GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1: a double-blind, randomized, phase 3 trial." *Lancet* Vol 398(10295) (2021): 143-155. doi.org/10.1016/s0140-6736(21)01324-6.
4. Frias, Juan P et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." *N Engl J Med.* 385(6) (2021): 503-515. doi.org/10.1056/nejmoa2107519.
5. Ludvik, Bernhard et al. "Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial." *Lancet* 398(103000) (2021): 583-598. doi.org/10.1016/s0140-6736(21)01443-4.
6. Del Prato, Stefano et al. "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomized, open-label, parallel-group, multicentre, phase 3 trial." *Lancet* 398(10313) (2021): 1811-1824. doi.org/10.1016/s0140-6736(21)02188-7.
7. Dahl, Dominik et al. "Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes." *JAMA*327(6)(2022): 534-545. doi.org/10.1001/jama.2022.0078.
8. Eli Lilly and Company. A study of tirzepatide (LY3298176) insulin lispro (U100) in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin (SURPASS-6). <https://clinicaltrials.gov/ct2/show/NCT04537923?term=Tirzepatide&draw=2>. NLM identifier: NCT04039503. Accessed August 1, 2022.
9. Lin GA, Brouwer E, Nikitin D et al. Tirzepatide for type 2 diabetes; final report. Institute for Clinical and Economic Review, February 15, 2022. <https://icer.org/assessment/diabetes-type-2-2022/#timeline>

**DISCLAIMER:** Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.